In a trial involving 13 pregnancies at high risk for early-onset severe hemolytic disease of the fetus and newborn, nipocalimab increased the percentage with live birth at 32 weeks’ gestation or later without intrauterine transfusions.
The New England Journal of Medicine: Search Results in Pediatrics
